Analysts’ Opinions Are Mixed on These Healthcare Stocks: CG Oncology, Inc. (CGON) and Zimmer Biomet Holdings (ZBH)

CG Oncology Price Target Raised to $85.00/Share from $82.00 by Truist Securities

RBC Adjusts PT on CG Oncology to $79 From $81, Maintains Outperform Speculative Risk Rating

Zentalis Q2 Net Loss Widens on Higher R&D Costs

Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)

TriSalus Life Sciences Q2 Revenue Beats Estimates

Biopharma Firm IN8bio's Q2 Net Loss Narrows as Expenses Decline

CG Oncology, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

CG Oncology Publishes Investor Deck Highlighting Cretostimogene Data in High-Risk NMIBC Programs

CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate

CG Oncology Q2 Net Loss Widens on Higher R&D Costs

Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.90 a Share, vs. FactSet Est of $0.66 Loss

CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Q2 EPS USD -0.9

CG Oncology Inc - Files for Offering of up to $500 Mln Common Stock - SEC Filing

Health Rounds: Experimental Cell Therapy Slows Heart Failure Progression in Duchenne Muscular Dystrophy

Analysts Have Conflicting Sentiments on These Healthcare Companies: Phibro Animal Health (PAHC), Universal Health (UHS) and CG Oncology, Inc. (CGON)

CG Oncology announces publication of BOND-003 results in The Lancet Oncology

CG Oncology Says Phase 3 Bond-003 Data for Cretostimogene in BCG-unresponsive Bladder Cancer Publish in Lancet Oncology

CG Oncology Director Leonard Post Disposes of 1,000 Shares for $71,170